StreetInsider.com News Articles

Amgen (AMGN) PT Raised to $303 at Mizuho

Tue, 16 Jun 2026 06:42:40 -0400

(Updated - June 16, 2026 6:42 AM EDT)

Mizuho analyst Salim Syed raised the price target on Amgen (NASDAQ: AMGN) to $303.00 (from $295.00) while maintaining a Neutral rating.

The analyst commented: "AMGN (N, increasing PT to $303): MariTide and olpasiran remain focal points; NVS/IONS' (both NC) pelacarsen Ph3 Lp(a) study reading out likely early 2H26 (could potentially be a tailwind to AMGN). Some potential risk w/ tax dispute outcome "no earlier than the 2H26". No major changes to our model (slight increase to medium-term sales profile, hence slight change to PT to $303 from $295). We imagine Street will start to

Amgen (AMGN) PT Raised to $303 at Mizuho

Tue, 16 Jun 2026 06:42:40 -0400

(Updated - June 16, 2026 6:42 AM EDT)

Mizuho analyst Salim Syed raised the price target on Amgen (NASDAQ: AMGN) to $303.00 (from $295.00) while maintaining a Neutral rating.

Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

Fri, 12 Jun 2026 08:25:26 -0400

Piper Sandler analyst David Amsellem reiterated an Overweight rating and $427.00 price target on Amgen (NASDAQ: AMGN).

The analyst commented: "With Phase III completion for Amgen’s CD40 ligand-directed fusion protein dazodalibep in Sjogren's syndrome expected in 2H26, we are taking a detailed look at the drug development landscape in this setting and how one should contextualize results (particularly with AMGN running studies in two separate Sjogren’s subgroups: moderateto-severe systemic disease activity and moderate-to-severe symptomatic burden with low systemic disease activity). Our Sjogren’s “cheat sheet” on the later-stage and earlier-stage development landscape (refer to Exhibits 1/2, and 3, respectively) is what we

Form 11-K AMGEN INC For: Dec 31

Thu, 11 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260611/26636028.html

Form 11-K AMGEN INC For: Dec 31

Thu, 11 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260611/26636028.html

Form 11-K AMGEN INC For: Dec 31

Thu, 11 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260611/26636009.html

Form 11-K AMGEN INC For: Dec 31

Thu, 11 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260611/26636009.html

Amgen (AMGN) PT Raised to $340 at Morgan Stanley

Tue, 09 Jun 2026 16:38:25 -0400

(Updated - June 9, 2026 4:38 PM EDT)

Morgan Stanley analyst Terance Flynn raised the price target on Amgen (NASDAQ: AMGN) to $340.00 (from $332.00) while maintaining a Overweight rating.

The analyst comments "AMGN has a portfolio of innovative drugs further supported by the recent acquisition of Horizon, but a number of large legacy franchises such as Prolia/Xgeva and Enbrel, among others face upcoming patent expiries. The outlook for the stock hinges on pipeline progress, with our focus mainly on MariTide (injectable) for obesity. We see obesity as a mega-blockbuster category that can support multiple players, representing upside for AMGN if they

Amgen (AMGN) PT Raised to $340 at Morgan Stanley

Tue, 09 Jun 2026 16:38:25 -0400

(Updated - June 9, 2026 4:38 PM EDT)

Morgan Stanley analyst Terance Flynn raised the price target on Amgen (NASDAQ: AMGN) to $340.00 (from $332.00) while maintaining a Overweight rating.

AMGEN's Repatha shows 29% cardiovascular event reduction in diabetes study

Mon, 08 Jun 2026 02:56:12 -0400

AMGEN Inc. (NASDAQ: AMGN) presented clinical trial data showing its cholesterol-lowering drug Repatha reduced major cardiovascular events by 29% in people with high-risk diabetes, according to results from the VESALIUS-CV trial subgroup analysis presented at the American Diabetes Association's 86th Scientific Sessions.

The analysis included 6,002 patients with high-risk diabetes who had elevated LDL cholesterol but no prior heart attack or stroke. Patients receiving Repatha alongside statins or other cholesterol-lowering therapies showed a 29% reduction in the composite primary endpoint of coronary heart disease death, heart attack, or stroke compared to placebo. The drug also reduced a broader composite endpoint including

AMGEN's Repatha shows 29% cardiovascular event reduction in diabetes study

Mon, 08 Jun 2026 02:56:12 -0400

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Sun, 07 Jun 2026 16:45:00 -0400